Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Philip D HomeRory J McCrimmon Julio RosenstockMatthias BlüherKatrin PegelowLydie Melas-MeltKhier DjaballahFrancesco Giorginonull null

Published in: Diabetes, obesity & metabolism (2022)

Treatment effects of iGlarLixi were consistent irrespective of baseline HbA1c, insulin dose, BMI, age, duration of diabetes and renal function, supporting the use of iGlarLixi as an efficacious and well-tolerated treatment option in people with type 2 diabetes with a wide range of biomedical characteristics.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
metabolic syndrome
combination therapy
replacement therapy